Drug Type Antibody |
Synonyms- |
Target |
Action agonists |
Mechanism α3β1 agonists(Integrin alpha 3/beta 1 agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Glomerulosclerosis, Focal Segmental | Preclinical | United States | 07 Nov 2025 | |
| Glomerulosclerosis, Focal Segmental | Preclinical | United States | 07 Nov 2025 | |
| Kidney Diseases | Preclinical | United States | 10 Oct 2022 |






